 The study found that 43.3% of U.S. adults aged greater than or equal to 65 received the 13-valent pneumococcal conjugate vaccine, PCV13, by November 2017, with disparities in uptake existing based on race ethnicity, annual household income, education status, and neighborhood ethnicity. This article was authored by John M. McLaughlin, David L. Swadlow, Farid Khan, and others.